Positive News SentimentPositive NewsNASDAQ:XGN Exagen (XGN) Stock Price, News & Analysis $9.85 +0.11 (+1.16%) Closing price 03:59 PM EasternExtended Trading$9.86 +0.00 (+0.02%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Exagen Stock (NASDAQ:XGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Exagen alerts:Sign Up Key Stats Today's Range$9.59▼$10.0050-Day Range$6.74▼$10.1052-Week Range$2.38▼$10.34Volume103,006 shsAverage Volume231,131 shsMarket Capitalization$216.77 millionP/E RatioN/ADividend YieldN/APrice Target$11.25Consensus RatingBuy Company Overview Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Read More Exagen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreXGN MarketRank™: Exagen scored higher than 74% of companies evaluated by MarketBeat, and ranked 271st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingExagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageExagen has only been the subject of 4 research reports in the past 90 days.Read more about Exagen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($0.88) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 10.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exagen's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.41% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Exagen has recently increased by 52.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.29 Percentage of Shares Shorted10.41% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Exagen has recently increased by 52.83%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment1.77 News SentimentExagen has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Exagen this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Exagen to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have not sold or bought any company stock.Percentage Held by Insiders12.60% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exagen's insider trading history. Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XGN Stock News HeadlinesExagen Inc. to Participate in Third Quarter Investor ConferencesAugust 6, 2025 | gurufocus.comExagen Inc. to Participate in Third Quarter Investor ConferencesAugust 6, 2025 | globenewswire.comThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.August 29 at 2:00 AM | Paradigm Press (Ad)BTIG Sticks to Their Buy Rating for Exagen (XGN)August 2, 2025 | theglobeandmail.comExagen (XGN) Receives a Buy from Craig-HallumAugust 1, 2025 | theglobeandmail.comExagen Inc. Reports Record Revenue Amidst Growth ChallengesAugust 1, 2025 | theglobeandmail.comCanaccord Genuity Sticks to Its Buy Rating for Exagen (XGN)July 31, 2025 | theglobeandmail.comXGN | Exagen Inc. Annual Cash Flow Statement | MarketWatchJuly 31, 2025 | marketwatch.comSee More Headlines XGN Stock Analysis - Frequently Asked Questions How have XGN shares performed this year? Exagen's stock was trading at $4.10 at the beginning of 2025. Since then, XGN stock has increased by 140.3% and is now trading at $9.8530. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) announced its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). The company earned $17.20 million during the quarter, compared to analysts' expectations of $16.25 million. Exagen had a negative net margin of 28.85% and a negative trailing twelve-month return on equity of 130.38%. Read the conference call transcript. When did Exagen IPO? Exagen (XGN) raised $50 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO. Who are Exagen's major shareholders? Top institutional shareholders of Exagen include Balyasny Asset Management L.P. (3.27%), Kennedy Capital Management LLC (1.41%), Russell Investments Group Ltd. (1.00%) and FourWorld Capital Management LLC (0.95%). Insiders that own company stock include Nmsic Co-Investment Fund, LP, James L L Tullis, John Aballi, Kamal Adawi and Mark Hazeltine. View institutional ownership trends. How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exagen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), Cassava Sciences (SAVA), CNX Resources (CNX) and Ford Motor (F). Company Calendar Last Earnings7/29/2025Today8/29/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealthcare Current SymbolNASDAQ:XGN CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Price Target for Exagen$11.25 High Price Target$12.00 Low Price Target$10.00 Potential Upside/Downside+15.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.11 million Net Margins-28.85% Pretax Margin-28.76% Return on Equity-130.38% Return on Assets-34.69% Debt Debt-to-Equity Ratio1.06 Current Ratio4.95 Quick Ratio4.95 Sales & Book Value Annual Sales$55.64 million Price / Sales3.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.96 per share Price / Book10.15Miscellaneous Outstanding Shares22,000,000Free Float19,231,000Market Cap$214.28 million OptionableOptionable Beta1.61 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:XGN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.